Comparative analysis of apoptotic resistance of mesenchymal stem cells isolated from human bone marrow and adipose tissue.
Ertaş G., Ural E., Ural D., Aksoy A., Kozdağ G., Gacar G.
Laboratory Study with a reported sample of 3, published in ScientificWorldJournal (2012) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Laboratory Study
- Journal
- ScientificWorldJournal (2012)
- Country
- United States
- Reported sample size
- 3
- Source database
- PubMed
- PMID
- 22619573
- DOI
- 10.1100/2012/105698
Abstract (original English)
Mesenchymal stem cells (MSCs) isolated from human bone marrow (hBM) and adipose tissue (hAT) are perceived as attractive sources of stem cells for cell therapy. The aim of this study was to compare MSCs from hBM and hAT for their immunocytochemistry staining and resistance to in vitro apoptosis. In our study, we investigated the antiapoptotic ability of these MSCs toward oxidative stress induced by hydrogen peroxide (H(2)O(2)) and serum deprivation. Results were assessed by MTT and flow cytometry. All experiments were repeated a minimum of three times. Flow cytometry and MTT analysis revealed that hAT-MSCs exhibited a higher resistance toward H(2)O(2)-induced apoptosis (n = 3, hBM-hAT viability H(2)O(2) 58.43 ± 1.24-73.02 ± 1.44, P < 0.02) and to serum-deprivation-induced apoptosis at days 1 and 4 than the hBM-MSCs (n = 3, hAT-hBM absorbance, resp., day 1: 0.305 ± 0.027-0.234 ± 0.015, P = 0.029, day 4: 0.355 ± 0.003-0.318 ± 0.007, P = 0.001, and day 7: 0.400 ± 0.017-0.356 ± 0.008, P = 0.672). hAT-MSCs showed superior tolerance to oxidative stress triggered by 2 mmol/L H(2)O(2) and also have superior antiapoptosis capacity toward serum-free culture. In this study we found that hAT-MSCs are more resistant to in vitro apoptosis.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.